IMMUPHARMA PLC — Director's Dealing 2017

Aug 18, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4650O

Immupharma PLC

18 August 2017

18 August 2017

ImmuPharma Plc

AIM Rule 17 Notice

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces pursuant to Rule 17 of the AIM Rules for Companies ("AIM Rules"), the following director's disclosure under Schedule Two, Paragraph (g) of the AIM Rules:

Tim McCarthy, the Company's Non-executive Chairman, previously held roles on the boards of Alizyme Plc and its subsidiary Alizyme Therapeutics Ltd, both of which entered into a Creditors Voluntary Winding-up in December 2009, within 12 months of his resignation.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Ends

For further information please contact:

ImmuPharma plc (www.immupharma.org)	+ 44 (0) 20 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor Relations Twitter: @immupharma	+ 44 (0) 7721 413496
Northland Capital Partners Limited (NOMAD & Broker) Patrick Claridge, David Hignell, Jamie Spotswood, Corporate Finance Rob Rees, Corporate Broking	+44 (0)20 3861 6625

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCOKFDKABKDOFD